|
16 Mar 2018 |
TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research
|
|
14 Mar 2018 |
Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
|
|
14 Mar 2018 |
Phase 1 clinical trial for Hantavirus vaccines yields positive interim results
|
|
13 Mar 2018 |
Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya
|
|
13 Mar 2018 |
Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program
|
|
08 Mar 2018 |
Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
|
|
08 Mar 2018 |
VBL Therapeutics Announces Top-Line Results from Pivotal Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma
|
|
05 Mar 2018 |
Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
|
|
02 Mar 2018 |
AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs® PD01A and PD03A, Confirming Safety and Tolerability for Both Compounds as well as Immunogenicity for PD01A in Early MSA patients
|
|
01 Mar 2018 |
Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine
|
|
28 Feb 2018 |
Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
|
|
27 Feb 2018 |
Emergent BioSolutions and Valneva initiate phase 1 clinical study to evaluate vaccine candidate against Zika virus
|
|
27 Feb 2018 |
DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk- Allergic Patients
|
|
26 Feb 2018 |
Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers
|
|
22 Feb 2018 |
OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Metastatic Triple Negative Breast Cancer
|
|
20 Feb 2018 |
Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
|
|
19 Feb 2018 |
Results from Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential for New BCG Revaccination Strategies, Hope For Subunit Vaccines
|
|
13 Feb 2018 |
CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria
|
|
13 Feb 2018 |
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
|
|
13 Feb 2018 |
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer
|
|
08 Feb 2018 |
GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
|
|
07 Feb 2018 |
Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine
|
|
06 Feb 2018 |
Argos Obtains Option to License PD1 Checkpoint Inhibitors
|
|
01 Feb 2018 |
Panacea Pharmaceuticals Completes Enrollment in Phase 1 Study of First-in-Class Cancer Vaccine Therapy in Patients with Persistent Prostate Cancer
|
|
01 Feb 2018 |
Vaxart Announces Its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study
|
